Drug Profile
Naproxen - Iroko Pharmaceuticals
Alternative Names: IP-890; Nano-formulated naproxen - Iroko Pharmaceuticals; SoluMatrix® NaproxenLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator iCeutica
- Developer Iroko Pharmaceuticals
- Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dental pain; Musculoskeletal pain
Most Recent Events
- 04 Jun 2019 Naproxen - Iroko Pharmaceuticals is available for licensing as of 31 Dec 2018
- 31 Jan 2019 Egalet completes acquisition of naproxen from Iroko Pharmaceuticals
- 31 Dec 2018 Discontinued - Phase-II for Dental pain in USA (PO), as the company is exploring possibilities for further development